Kornimate/medical-research-clean huggingface dataset:
nanofat grafting as a method of treating critical limb ischemia

Conditions: Limb Ischemia

Summary: this clinical trial will investigate nano fat grafting as a method for treating critical limb ischemia. the method involves the collection of adipose tissue under tumescent anesthesia through a separate incision in the anterior abdominal wall, followed by preparation and injection of nano fat into the tissues of the foot and leg without additional drug therapy. the novelty of this method lies in the use of autologous stem cells and growth factors, differing from current treatments like neovasculgen, which is a plasmid dna-based treatment. the trial aims to assess the safety and effectiveness of nano fat grafting, including pain relief, the frequency of intraoperative complications, increased distance of pain-free walking, limb preservation, and mortality rates. the trial will involve patients with diagnosed occlusive lesions of the femoral-popliteal-tibial segment and chronic ischemia of iii-iv degree according to fontaine and 5-6 categories according to rutherford, excluding those with contraindications for surgical intervention on the femoral-popliteal-tibial segment, chronic heart failure of iii-iv nyha class, severe liver or kidney failure, among others. the study design includes preoperative examinations, hospital phase activities including the surgery and post-operative assessments, and follow-up visits at 6 and 12 months post-operation to evaluate the method's safety, complications, and effectiveness based on various parameters like pain, trophic disturbances, and limb ischemia severity. statistical methods will involve quantitative data presented as mean ± standard deviation, with qualitative traits compared using the chi-square test or fisher's exact test. the planned patient number is 40, aiming to demonstrate the effectiveness and safety of nano fat grafting for critical limb ischemia treatment compared to current treatments.


Eligibility criteria:
inclusion criteria: * patients with occlusive lesions of the femoral-popliteal-tibial segment. * chronic ischemia of the lower limbs of iii-iv degree according to fontaine and categories 5-6 according to rutherford. * signed informed consent for participation in the clinical trial. exclusion criteria: * absence of indications for surgical intervention on the femoral-popliteal-tibial segment. * patients refusing to participate in the clinical trial. * chronic heart failure of iii-iv nyha functional class. * chronic decompensated "pulmonary" heart. * severe liver or kidney failure (bilirubin \>35 mmol/l, glomerular filtration rate \<60 ml/min). * polivalent drug allergy. * malignant oncological diseases in the terminal stage with a life expectancy of less than 6 months. * acute cerebrovascular accident. * decompensated diseases of the endocrine organs (for diabetes, glycemia level more than 10 mmol/l). * pregnancy and lactation period. * inability to undergo examinations at control points. * refusal to sign informed consent for participation in the clinical trial.

Keywords: nano fat grafting critical limb ischemia autologous stem cells limb preservation
oral peanut immunotherapy for peanut allergic patients

Conditions: Peanut Hypersensitivity

Summary: this is a study to determine if peanut oral immunotherapy (oit) would desensitize or tolerize peanut allergic patients to peanuts in order prevent peanut allergic reactions.

the goal of this proposal is to develop peanut oit for patients with peanut allergic reactions. this approach is designed to utilize our extensive knowledge of the allergens involved in peanut hypersensitivity to devise an immunotherapeutic approach that would lower the risk of anaphylactic reactions and would down regulate peanut-specific t cells in peanut-allergic patients. previous attempts to utilize peanut-specific immunotherapy (it) have been unsuccessful primarily because of the side effects of therapy.

Eligibility criteria:
inclusion criteria: * subjects between 1 and 16 years of age * diagnosed peanut allergy by either: 1) a positive prick skin test to peanut, cap feia of 15 or greater and a history of significant clinical symptoms within one hour after ingestion of peanuts or 2) a positive prick skin test to peanut, cap feia of ≥ 7 and a history of a clinical reaction to peanut ingestion within the past 6 months. * a family that will be able to be compliant with all study visits. exclusion criteria: * subjects with a history of severe anaphylaxis to peanut * subjects with a medical history that would prevent a dbpcfc/ofc to peanut the medical history that would prevent the dbpcfc to peanut would be a prior history of an open peanut challenge in which the patient experienced hypotension which required fluid resuscitation, respiratory compromise which necessitated ventilatory support, or poorly controlled asthma as evidenced by an forced expiratory volume in 1 second (fev1) \< 80% of predicted, or fev1/fvc (forced vital capacity) \< 75%, with or without controller medications * subjects unable to cooperate with challenge procedures or unable to be reached by telephone for follow-up * pregnant or lactating * allergy to oat

Keywords: peanut allergy
inflammatory response and gingival inos levels in diabetic vs. non-diabetic periodontitis patients

Conditions: Periodontitis; Type 2 Diabetes; Glycemic Control

Summary: this study investigates the relationship between type 2 diabetes mellitus (t2dm), glycemic control, and periodontal disease. researchers analyzed the levels of inducible nitric oxide synthase (inos) and proinflammatory cytokines, such as tumor necrosis factor-alpha (tnf-α), interleukin-1 beta (il-1β), and interferon-gamma (ifn-γ), in 118 participants. the participants were categorized based on their periodontal and diabetes control status.

this study is an observational analysis using a cross-sectional time perspective and explores the interplay between type 2 diabetes mellitus (t2dm), glycemic control, and periodontal disease by evaluating the expression of inducible nitric oxide synthase (inos) and proinflammatory mediators (tnf-α, il-1β, ifn-γ, and pge2) in gingival tissues. a total of 118 participants were classified into six groups based on their periodontal health and glycemic control status, determined by hba1c levels. gingival biopsies were collected and analyzed using elisa to measure biomarker levels. the study found significant differences in inflammatory marker concentrations between groups, with poorly controlled t2dm participants showing markedly higher levels of inos and cytokines. this aligns with the hypothesis that poor glycemic control amplifies periodontal inflammation and oxidative stress, contributing to tissue destruction. the findings underline the critical role of glycemic regulation in managing periodontal disease and suggest potential targets, such as inos, for therapeutic interventions. this study adheres to ethical standards, including informed consent and approval by the ondokuz mayis university clinical research ethics committee. the results emphasize the bidirectional relationship between diabetes and periodontal health, contributing to a better understanding of the systemic implications of periodontal inflammation.

Eligibility criteria:
inclusion criteria: * participants must be between 18 and 65 years of age (according to the world health organization definition of young and adult individuals). * diagnosed with periodontitis (stage 2, 3, or 4) based on the 2017 classification of periodontal diseases and conditions. * diabetes control status determined by hba1c levels: controlled diabetes: hba1c ≤ 7, uncontrolled diabetes: hba1c \> 7 * must volunteer and sign an informed consent form for clinical evaluations and collection of tissue samples. exclusion criteria: * history of smoking. * presence of systemic or local diseases affecting the immune system (e.g., autoimmune disorders, hiv, hepatitis). * pregnant or breastfeeding individuals. * history of antibiotic use or periodontal treatment within the last 3-6 months. * history of immunosuppressive therapy or chemotherapy. * requirement for antibiotic prophylaxis. * severe systemic illnesses unrelated to diabetes (e.g., cancer, cardiovascular diseases).

Keywords: periodontitis diabetes inos glycemic control
safety and immunogenicity of a commercially available influenza vaccine (formulation 2007/2008) when administered to elderly subjects

Conditions: Influenza

Summary: to evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over


Eligibility criteria:
inclusion criteria: - 65 years of age or older exclusion criteria: * any serious disease such as cancer, autoimmune disease, advanced arteriosclerotic disease or insulin-dependent diabetes mellitus, chronic obstructive pulmonary disease (copd) that requires oxygen therapy, acute or progressive hepatic disease, acute or progressive renal disease, congestive heart failure and bleeding diathesis or conditions associated with prolonged bleeding time * hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or kanamycin or any other component of the vaccine * history of neurological symptoms or signs, or anaphylactic shock following administration of any vaccine * known or suspected (or high risk of developing) impairment/alteration of immune function * any acute disease or infections requiring systemic antibiotic or antiviral therapy within the past 7 days * fever within the past 3 days

Keywords: adjuvanted influenza vaccine
rst-001 phase i/ii trial for advanced retinitis pigmentosa

Conditions: Advanced Retinitis Pigmentosa

Summary: currently enrolling a total of 12 patients for phase 2a of the study: 6 patients must have va of no-better-than hand motion in the study eye, and 6 patients must have va in the study eye to range from no-worse-than count fingers to 20/200 vision.


Eligibility criteria:
inclusion criteria: participants must meet all of the following criteria. 1. age \>= 18 years 2. signed and dated written informed consent obtained from the patient. 3. ability to comply with testing and all protocol tests. exclusion criteria: any one of the following will exclude patients from being enrolled into the study: 1. unable or unwilling to meet requirements of the study; 2. participation in a clinical study (ocular or non-ocular) with an investigational drug, agent or therapy in the past six months

Keywords: gene therapy optogenetics channelrhodopsin retina retinitis pigmentosa
comparison of standard and hybrid surgical techniques in the treatment of proximal aortic dissections

Conditions: State of Non-operated Aortic Segments; Aorto-related Events

Summary: the study is devoted to the evaluation of the results of surgical treatment of patients with proximal aortic dissection. two groups of patients with standard and hybrid surgery are compared. early and long-term postoperative results are evaluated.


Eligibility criteria:
inclusion criteria: * aortic dissection type a exclusion criteria: * age limits
resistive co-contraction training after anterior cruciate ligament reconstruction

Conditions: Muscle Weakness

Summary: this study investigates different resistive co-contraction trainings effect on knee strength recovery after acl reconstruction. participants will be divided into three groups. group 1 will receive standard acl rehabilitation with 8 week co-contraction training in open kinetic chain position, group 2 will receive standard acl rehabilitation with 8 week co-contraction training in open kinetic chain position and group 3 (control group) will only receive standard acl rehabilitation.

co-contraction trainings can enhance joint stability via improving proprioceptive ability and stimulates muscle activity after injury and/or surgery. the participants will be assigned to the different groups one month after surgery. they will receive 8-week-treatment. isometric strength of quadriceps and hamstring muscles will be measured at first,third and sixth months after surgery. concentric and eccentric strength of quadriceps and hamstring muscles will be measured only at sixth months after surgery.

Eligibility criteria:
inclusion criteria: * acl reconstruction with hamstring autograft * starting pt program within one week after surgery exclusion criteria: * revision surgery * serious cartilage damage and/or cartilage repair * acl reconstruction with allograft and patellar tendon graft * having systemic and/or neurological problems

Keywords: knee joint muscle strength anterior cruciate ligament
trial evaluating the efficacy of laying a biliary stent for producing a heavy chemotherapy in unresectable pancreatic adenocarcinomas

Conditions: Adenocarcinoma of Head of Pancreas

Summary: for many years, the treatment of jaundice due to head pancreatic adenocarcinoma is based on the endoscopic biliary stent. this technique has been shown to be preferable to a surgical shunt. recently, adjuvant chemotherapy with folfirinox regimen (clinical trial) has revolutionized the treatment of metastatic pancreatic adenocarcinoma increasing overall survival in a major way. this design will also be developed in patients with neoadjuvant tumor called "borderline" (the limit of the resectability). however, several conditions (protocol) are required to consider the implementation of this design : age ≤ 75 years, ps 0 or 1, good hematological parameters and bilirubin ≤ 1.5 times the uln. in addition, a randomized study showed that preoperative biliary stent treatment, despite a success rate of 94%, is associated with more complications than surgery fast (related gesture bladder). it would be interesting to analyze, prospectively, the fate of a series of patients with cancer of the pancreatic head with compression of the lower part of the bile duct, ps 0 or 1 and for which the only limit to folfirinox design is jaundice or high risk of jaundice.


Eligibility criteria:
inclusion criteria: * patient aged \> 18 ans and ≤ 75 ans * suspicion of adenocarcinoma of the head of the pancreas leading to the placement of a biliary stent * either metastatic or "borderline" (at the limit of resectability) or locally advanced * ps = 0 or 1 * hematological laboratory parameters (anc ≥ 1.5 \*\* 10 9 / l (/ mm3), platelets ≥ 100 \*\* 10 9 / l (g / l)) and kidney (calculated creatinin clearance\> 60 ml / min) * jaundice (bilirubin\> 20 mmol / l) by compressing the lower part of the bile duct (dilatation of the extrahepatic bile duct) * written informed consent * affiliation to social security exclusion criteria: * pregnant or lactating woman or without contraception (for child bearing potential women) * patient deprived of liberty or under supervision of a guardian * impossibility to undergo medical examinations of the study for geographical, social or psychological reasons * contra-indication for study procedure * predictable technical impossibility to position a stent endoscopically (prior upper gi surgery) * life expectancy assumed less than 3 months

Keywords: laying of the biliary stent
safety and efficacy of aprepitant, ramosetron, and dexamethasone for chemotherapy-induced nausea and vomiting in patients with ovarian cancer treated with taxane/carboplatin

Conditions: Chemotherapy-Induced Nausea and Vomiting; Ovarian Cancer

Summary: the current recommended guideline for patients receiving moderately emetogenic chemotherapy (mec) is the combination of a 5-ht3 receptor antagonist and corticosteroid. incidence of chemotherapy induced nausea and vomiting (cinv) is approximately 50% in patients receiving mec. an incidence rate of 25-38% for delayed emesis and 55-60% for delayed nausea has been observed. hence, there is clearly a need for more effective prevention of cinv in patients receiving mec, especially in women with ovarian carcinoma who are particularly susceptible to these symptoms. therefore the investigators designed a study with the objective to evaluate if new combination (aprepitant/ramosetron/dexamethasone) may improve actual cinv control in ovarian carcinoma patients treated with taxane/carboplatin.


Eligibility criteria:
inclusion criteria 1. patient is over 18 years 2. ovarian carcinoma patients who are treated with moderately emetogenic chemotherapy 3. karnofsky score \> 60 4. life expectancy \> 4 months exclusion criteria 1. any of following conditions (mentally incapacitated or emotional or psychiatric disorder, user of any illicit drugs, has an active infection, hypersensitivity to ramosetron or aprepitant) 2. patients have received a nonapproved drug within last 4 weeks 3. abnormal laboratory values (ast \> 2.5 normal, alt \> 2.5 normal, bilirubin \> 1.5 normal, creatinine \> 1.5 normal) 4. antiemetic drugs within 48 hours of study 5. benzodiazepine or opiate within 48 hours 6. cyp3a4 substrates within 7 days (terfenadine, cisapride, astemizole, pimozide) 7. cyp3a4 inhibitors (clarithromycin, ketoconazole) 8. cyp3a4 inducers within 30 days (barbiturates, rifampicin, carbamazepine)

Keywords: efficacy and safety of aprepitant/ramosetron/dexamethasone in ovary cancer patients with taxol and carboplatin
gnrh antagonist versus gnrh agonist in polycystic ovary syndrome during in vitro fertilization - embryo transfer

Conditions: Infertility; Polycystic Ovary Syndrome

Summary: gnrh (gonadotropin-releasing hormone) antagonists in ivf (in vitro fertilization) has been accomplished by several randomized controlled trials compared with conventional gnrh agonist long protocol in polycystic ovary syndrome (pcos) patients. moreover, there are debating issues that refer to the timing of gnrh antagonist initiation. the purpose of this study is to investigate the laboratory and clinical priority during ovarian stimulation for ivf in patients with pcos treated with three different protocols.

gnrh antagonist is started on stimulation day 1 gnrh antagonist is started on stimulation day 6 conventional gnrh agonist long protocol

Eligibility criteria:
inclusion criteria: * pcos patients (diagnosed as 2003 asrm(the american society for reproductive medicine)/eshre(the european society of human reproduction and embryology) consensus meeting guideline) * age 20-40 years * patients who have normal uterus * korean ethnicity exclusion criteria: * patients who have abnormal thyroid function * patients who have abnormal prolactin test * patients who have diabetes, or cushing's syndrome, or congenital adrenal hyperplasia, or androgen-producing tumor. * patients who reject informed consent * patients who have experience of adverse events for gnrh agonist, antagonist, recombinant fsh(follicle-stimulating hormone).

Keywords: polycystic ovary syndrome ovulation induction in vitro fertilization-embryo transfer
comparison of regional manual therapy and standard physical therapy intervention in females with sacroiliac joint pain

Conditions: Sacroiliac; Sprain (Strain)

Summary: the sij has long been considered an important source of low back pain because of the empirical ﬁnding that treatment targeting the sij can relieve pain.this study was be a randomized clinical trail conducted at riphah rehabilitation centre lahore. the study was be completed within the time duration of six months. purposive sampling technique was be used. sample size is calculated by using the g power 3.1. the sample size of 64 patients was be taken in this study to find the comparison of regional manual therapy and standard physiotherapy intervention in females with sacroiliac joint pain. patients was be divided into two groups.. patients was be divided into two groups. group a was be treated with regional manual therapy. in regional manual therapy patients was be given mobilization to lumber region and sij, pelvic floor exercises and core strengthening exercises and group b was be treated with standard physiotherapy in which patients was be given sij mobilization and straight leg raise. both groups was receive transcutaneous electrical nerve stimulator and heating pad as a common treatment protocol. numeric pain rating scale (nprs) and oswestry low back disability questionnaire was be used as data collecting tools. two session of treatment per week for eight weeks was be given. data was be analyzed on spss 21.


Eligibility criteria:
inclusion criteria: * females with sacroiliac joint pain * age: 20 to 50 years exclusion criteria: * patients withany red flag signs i.etumor, fracture, metabolic diseases, rheumatoid arthritis, prolonged history of steroids use, etc. * females with sciatica * females with radiating pain
wireless handheld 8-lead ecg device performance in heart patients (rapid rhythm)

Conditions: Atrial Fibrillation; Heart Murmurs

Summary: this study is designed to compare the performance of both 6 and 10 electrode ecgs from the handheld device with the conventional 12 lead ecg. as well as comparing the detection of atrial fibrillation, the study will also compare the detection of other heart problems and of normal heart rhythm.

an electrocardiogram (ecg) 6 electrode, wireless handheld device held on the chest is being developed to allow diagnosis of heart rhythm problems without the need for connecting electrodes to the chest, arms and legs as in a standard 10 electrode (referred to as a 12-lead) ecg measurement. a faster and simpler yet accurate method for acquiring ecg data may be useful in many healthcare settings, including screening for irregular heart rhythms such as atrial fibrillation (af), which is a risk factor for stroke. the wireless 6 electrode device has an extension arm for the handset with 4 additional electrodes (also positioned on the chest) to give a full 12 lead ecg signal. this study is designed to compare the performance of both 6 and 10 electrode ecgs from the handheld device (used on the chest with the subject seated) with the conventional 12 lead ecg (used with electrodes on the chest, arms and legs with the subject lying down). as well as comparing the detection of atrial fibrillation, the study will also compare the detection of other heart problems and of normal heart rhythm. adult patients attending the clinics at central manchester university hospitals nhs foundation trust for an ecg assessment are eligible to participate in the study. a maximum of 500 patients will be recruited to the study in order to find the number of cases with atrial fibrillation required to properly compare the methods. a subset of patients with normal ecgs will have additional measurements with both methods whilst lying down, reclining at an angle and sitting upright to investigate any effects of body posture on chest based ecgs.

Eligibility criteria:
inclusion criteria: 1. patient attending an adult cardiology or anti-coagulation clinic appointment, at clinics at central manchester university hospitals nhs foundation trust (including the manchester heart centre). 2. patients on cardiac wards 3 and 4. 3. aged 18 years or above. 4. male or female. exclusion criteria: 1. aged less than 18 years. 2. unable to give informed consent. 3. does not wish to participate in the study. 4. any patients with visible breaks to the skin, rashes or inflammation in the chest area on the day of the test 5. bedridden or otherwise unable to transfer between chair and bed for both seated and supine measurements
community-based tai chi, balance, and fall risk

Conditions: Postural Balance; Fall; Proprioceptive Disorders

Summary: aims: examine the effects of a community tai chi program on measures of balance and sensorimotor function. methods: in a pre-test and post-test design, balance was measured in older adults (n=344; 73.4±7.4 years) with 30-second chair stand, timed-up and go, and 4-stage balance test following a 12-week community-based tai chi intervention. balance measures and additional sensorimotor measures, including hip abductor electromechanical delay and hip proprioception, were measured in a smaller sample of older adults (n=11; 67.3±3.7 years).


Eligibility criteria:
inclusion criteria: * age 60 years or older * ability to independently ambulate * self-described concern with stability and/or mobility. exclusion criteria: * neurological diagnosis * participants body weight exceeds \>450 pounds).